Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Comparative analysis of laboratory examination data of patients with T2DM with and without sarcopeniaItemT2DM without sarcopenia (n = 221)T2DM with sarcopenia (n = 61)PFBG(mmol/L)7.23 ± 2.766.69 ± 2.050.153PBG(mmol/L)15.30 ± 3.9316.21 ± 4.970.280FCP(mmol/L)1.45(0.72,2.05)1.25(0.56,1.62)0.048HbA1c(%)8.60 ± 2.118.82 ± 2.190.461TG(mmol/L)1.38(0.94,2.26)1.11(0.79,1.63)0.028TC(mmol/L)4.08 ± 1.084.31 ± 1.220.147HDL-C(mmol/L)0.94(0.84,1.14)1.03(0.88,1.26)0.084LDL-C(mmol/L)2.64 ± 0.822.79 ± 0.940.179ALT(U/L)16.5(12.03,22.49)13.27(9.52,17.52)0.011AST(U/L)17.1(13.40,21.97)15.2(12.6,21.9)0.388Cr(mmol/L)75.63 ± 29.8369.38 ± 19.240.114UA(mmol/L)305.62 ± 82.05275.87 ± 68.990.009Alb(g/L)42.5(40.5,45.0)41.3(39.50,44.80)0.49925(OH)D(nmol/l)38.1(27.3,55.2)46.6(29.31,56.37)0.305BGP(ng/ml)12.87 ± 6.4212.36 ± 4.890.551PTH(pmol/l)3.84 ± 1.573.62 ± 1.370.305Ca(mmol/l)2.25 ± 0.992.24 ± 0.110.449ASMI(kg/m2)7.63 ± 3.156.18 ± 0.68< 0.001Left Upper Limb2.79 ± 0.662.08 ± 0.46< 0.001Right Upper Limb2.79 ± 0.602.09 ± 0.45< 0.001Left Lower Limb7.40 ± 1.375.98 ± 1.26< 0.001Right Lower Limb7.43 ± 1.386.05 ± 1.26< 0.001T2DM: type 2 diabetes mellitus; FBG: fasting blood glucose; PBG: postprandial blood glucose; FCP: fasting c-peptide, HbA1c: glycated hemoglobin; TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Cr: creatinine; UA: uric acid; Alb: albumin; 25(OH)D: 25-hydroxyvitamin D; BGP: serum osteocalcin; PTH: parathyroid hormone; Ca: serum calcium; ASMI: the Appendicular Skeletal Muscle Index.Measurement data that fit the normal distribution were represented by mean ± standard deviation, while those that did not fit the normal distribution were represented by median and interquartile range.
Source: Comparison of laboratory examination indicators between patients diagnosed with T2DM with and without sarcopenia. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Body mass index (BMI), and limb and trunk muscle mass of the patients were measured, and data were collected.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Relationship between sarcopenia and fatty liver in middle-aged and elderly patients with type 2 diabetes mellitus
Study design awaiting verification · Journal of Orthopaedic Surgery and Research · 2024
Original publication title
Relationship between sarcopenia and fatty liver in middle-aged and elderly patients with type 2 diabetes mellitus
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
In this study, we investigated the relationship between sarcopenia and fatty liver in middle-aged and elderly patients diagnosed with type 2 diabetes mellitus (T2DM) to provide a theoretical foundation for the prevention and treatment of sarcopenia.
Source: ObjectiveAbstract: What methods does the paper describe?
A total of 282 patients diagnosed with T2DM aged 50 and older and were admitted to the Endocrinology Department of Xin Medical University First Affiliated Hospital between December 2021 and February 2023, were selected. Body mass index (BMI), and limb and trunk muscle mass of the patients were measured, and data were collected. Patients were grouped based on the sarcopenia diagnostic criteria. All study participants underwent the same physical examinations and laboratory tests. The relationship between the onset of sarcopenia and fatty liver in middle-aged and elderly patients diagnosed with T2DM was then investigated using statistical analysis.
Source: MethodsAbstract: Results
Comparing the sarcopenia group to the non-sarcopenia group revealed statistically significant variations in gender, BMI, fatty liver prevalence rate, uric acid (UA), alanine aminotransferase (ALT), blood glucose, blood lipid associated indicators, and limb skeletal muscle content. There were, however, no statistically significant differences in age, disease duration, hypertension, smoking, or alcohol intake. There was a positive correlation between BMI, UA, fasting c-peptide, and Appendicular Skeletal Muscle Index (ASMI). Higher levels of BMI, ASMI, and UA were identified as protective variables against sarcopenia by multifactorial logistic regression analysis.
Source: ResultsAbstract: Conclusion
Higher levels of BMI, ASMI, and UA can greatly reduce skeletal muscle atrophy in patients with T2DM. Patients with a fatty liver may be less vulnerable to sarcopenia. There is little evidence, however, that a fatty liver works as a preventive factor against sarcopenia.
Source: ConclusionAuthors’ abstract
Objective
In this study, we investigated the relationship between sarcopenia and fatty liver in middle-aged and elderly patients diagnosed with type 2 diabetes mellitus (T2DM) to provide a theoretical foundation for the prevention and treatment of sarcopenia.
Methods
A total of 282 patients diagnosed with T2DM aged 50 and older and were admitted to the Endocrinology Department of Xin Medical University First Affiliated Hospital between December 2021 and February 2023, were selected. Body mass index (BMI), and limb and trunk muscle mass of the patients were measured, and data were collected. Patients were grouped based on the sarcopenia diagnostic criteria. All study participants underwent the same physical examinations and laboratory tests. The relationship between the onset of sarcopenia and fatty liver in middle-aged and elderly patients diagnosed with T2DM was then investigated using statistical analysis.
Results
Comparing the sarcopenia group to the non-sarcopenia group revealed statistically significant variations in gender, BMI, fatty liver prevalence rate, uric acid (UA), alanine aminotransferase (ALT), blood glucose, blood lipid associated indicators, and limb skeletal muscle content. There were, however, no statistically significant differences in age, disease duration, hypertension, smoking, or alcohol intake. There was a positive correlation between BMI, UA, fasting c-peptide, and Appendicular Skeletal Muscle Index (ASMI). Higher levels of BMI, ASMI, and UA were identified as protective variables against sarcopenia by multifactorial logistic regression analysis.
Conclusion
Higher levels of BMI, ASMI, and UA can greatly reduce skeletal muscle atrophy in patients with T2DM. Patients with a fatty liver may be less vulnerable to sarcopenia. There is little evidence, however, that a fatty liver works as a preventive factor against sarcopenia.
Publication and source details
Original title: Relationship between sarcopenia and fatty liver in middle-aged and elderly patients with type 2 diabetes mellitus
Li Quan; Fang Zhang; Jing Xu; Fei Wang; Yong Fan
Journal of Orthopaedic Surgery and Research · 2024
© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia FundSKL-HIDCA-2020-45Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T12:04:55.126573+00:00
DOI: 10.1186/s13018-024-04717-9 · PMC11031894